{
  "trial_id": "NCT02969083",
  "eligibility_criteria": "Inclusion Criteria:\n\n* Written informed consent\n* Age > 18 years\n* Histological and radiological defined UTUC: Histologically-confirmed diagnosis of predominantly urothelial carcinoma of the upper urinary tract Patients with UTUC cT2-pT4 cN0-N1 M0 (TNM classification)\n* Women with negative serum pregnancy test within 14 days of first dose of study treatment and agreement to use effective contraception\n* Patients without bladder cancer or with concomitant non muscle invasive bladder cancer\n* Adequate organ system function defined as follows: Hematologic: Absolute neutrophil count (ANC) 1.5 X 109/L; Haemoglobin 5.6 mmol/L (9.02g/dL); Platelets 100 X 109/L; Prothrombin time (PT) or international normalized ratio (INR)b 1.2 X ULN; Activated partial thromboplastin time (aPTT)1.2 X Upper limit of normal (ULN). Hepatic: Total bilirubin 1.5 X ULN; Alanine amino transferase (ALT) and Aspartate aminotransferase (AST) 2.5 X ULN. Renal: GRF <or> 55 ml/min: Electrolytes: potassium and calcium: within normal limits.\n* CT scan of the chest, abdomen and pelvis and Bone scan without evidence of distant metastasis\n\nExclusion Criteria:\n\n* Histology of pure adenocarcinoma, pure squamous cell carcinoma, sarcomatoid or predominant small cell carcinoma.\n* History of cardiovascular conditions within the past 6 months.\n* Incidentally found asymptomatic pulmonary embolism (PE) or recent deep vein thrombosis (DVT) is not an exclusion criteria but requires anticoagulation treatment.\n* Any major contraindication to a surgical procedure.\n* Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.\n* Active infection contraindicating chemotherapy\n* Other active neoplasms. Patients with in situ cervical carcinoma, non-melanoma skin cancer or prostate cancer T1 Gleason <7, Prostate specific antigen (PSA) <10. Patients with past medical history of cancer can be included if diagnosed at least 4 years ago.\n* Concomitant muscle invasive bladder cancer\n* Patients who have been or still are on methotrexate treatment.",
  "sanitised_criteria": "Inclusion Criteria:\n\n- Age > 18 years\n- Histologically-confirmed diagnosis of predominantly urothelial carcinoma of the upper urinary tract\n- Patients with UTUC cT2-pT4 cN0-N1 M0 (TNM classification)\n- Women with negative serum pregnancy test within 14 days of first dose of study treatment and agreement to use effective contraception\n- Patients without bladder cancer or with concomitant non-muscle invasive bladder cancer\n- Adequate organ system function defined as follows:\n  - Hematologic: Absolute neutrophil count (ANC) 1.5 x 10^9/L; Hemoglobin 5.6 mmol/L (9.02 g/dL); Platelets 100 x 10^9/L; Prothrombin time (PT) or international normalized ratio (INR) 1.2 x ULN; Activated partial thromboplastin time (aPTT) 1.2 x ULN\n  - Hepatic: Total bilirubin 1.5 x ULN; Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) 2.5 x ULN\n  - Renal: GFR â‰¥ 55 ml/min\n  - Electrolytes: potassium and calcium within normal limits\n- CT scan of the chest, abdomen, and pelvis and Bone scan without evidence of distant metastasis\n\nExclusion Criteria:\n\n- Histology of pure adenocarcinoma, pure squamous cell carcinoma, sarcomatoid or predominant small cell carcinoma\n- History of cardiovascular conditions within the past 6 months\n- Any major contraindication to a surgical procedure\n- Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety or compliance to study procedures\n- Active infection contraindicating chemotherapy\n- Other active neoplasms\n- Patients with in situ cervical carcinoma, non-melanoma skin cancer, or prostate cancer T1 Gleason <7, PSA <10\n- Patients with past medical history of cancer can be included if diagnosed at least 4 years ago\n- Concomitant muscle invasive bladder cancer\n- Patients who have been or still are on methotrexate treatment",
  "eligibility_groups": [
    "default"
  ]
}